Boston Scientific Corp. (NYSE:BSX) was granted U.S. Food & Drug Administration approval for leads designed for use in its Precision Plus spinal cord stimulator system.The Linear 3-4 and Linear 3-6 leads, when combined with the recently approved W4 and D4 lead splitters, provide physicians with the broadest range of percutaneous lead [...]

Boston Scientific Corp. (NYSE:BSX) launched two spinal cord stimulation lead splitters for use with its Precision Plus spinal cord stimulator system.The new design enables multi-site placement of up to four spinal cord leads designed to deliver electrical pulses that mask back pain signals on their way to the brain.Boston Scientificsaid in a press release the [...]

Boston Scientific Corp. (NYSE:BSX) enrolled the first patient in its Evidence clinical trial comparing spinal cord stimulation with second operations for patients whose first back surgeries failed.The Natick, Mass.-based medical device giant said the 132-patient trial will compare its Precision Plus spinal cord stimulator system with revision surgery to treat patients with failed back surgery [...]